Webinar
Additional NDC, due to Packaging Change of tivozanib (Fotivda®)
Date: October 3, 2025 | 2:00 PM
Medication changes can cause delays if teams aren’t ready. Starting October 6, 2025, the 1.34 mg and 0.89 mg strengths of tivozanib will have new NDCs because of a packaging update.
In this session, Mike McDole, MBA (AVEO Oncology) will explain what’s changing, how to update ordering and billing systems, and what to check now to avoid delays and confusion for your patients.
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.
Additional Upcoming Webinars
Upcoming Webinar
Updates in Breast Cancer: Antibody-Drug Conjugates and Cyclin-Dependent Kinase Inhibitors
June 15, 2026 | 2:00 PM
June 16, 2026 | 2:00 PM